Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Flisiak

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Alimentary Pharmacology & Therapeutics|August 5, 2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)S Zeuzem, R Flisiak, J M Vierling, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Alimentary Pharmacology & Therapeutics|September 10, 2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER studyR Flisiak, E Janczewska, M Wawrzynowicz-Syczewska, et al.
Journal of Viral Hepatitis|January 10, 2018
Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 studyR Flisiak, D Zarębska-Michaluk, E Janczewska, et al.
AIDS Care|July 27, 2019
Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 studyA Piekarska, E Jabłonowska, A Garlicki, et al.
Journal of Viral Hepatitis|January 27, 2016
Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conferenceG Papatheodoridis, H C Thomas, C Golna, et al.
Alimentary Pharmacology & Therapeutics|September 16, 2016
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis BP Marcellin, S H Ahn, W-L Chuang, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Journal of Viral Hepatitis|January 7, 2015
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2E Gane, D Kershenobich, C Seguin-Devaux, et al.
Journal of Viral Hepatitis|January 7, 2015
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2V Saraswat, S Norris, R J de Knegt, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Alimentary Pharmacology & Therapeutics|August 5, 2015
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)S Zeuzem, R Flisiak, J M Vierling, et al.
Journal of Viral Hepatitis|March 16, 2013
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirinG R Foster, S Zeuzem, S Pianko, et al.
Alimentary Pharmacology & Therapeutics|September 10, 2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER studyR Flisiak, E Janczewska, M Wawrzynowicz-Syczewska, et al.
Journal of Viral Hepatitis|January 10, 2018
Treatment of HCV infection in Poland at the beginning of the interferon-free era-the EpiTer-2 studyR Flisiak, D Zarębska-Michaluk, E Janczewska, et al.
AIDS Care|July 27, 2019
Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 studyA Piekarska, E Jabłonowska, A Garlicki, et al.
Journal of Viral Hepatitis|January 27, 2016
Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conferenceG Papatheodoridis, H C Thomas, C Golna, et al.
Alimentary Pharmacology & Therapeutics|September 16, 2016
Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis BP Marcellin, S H Ahn, W-L Chuang, et al.
Journal of Viral Hepatitis|January 7, 2015
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2A Hatzakis, V Chulanov, A C Gadano, et al.
Journal of Viral Hepatitis|January 7, 2015
Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2E Gane, D Kershenobich, C Seguin-Devaux, et al.
Journal of Viral Hepatitis|January 7, 2015
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2V Saraswat, S Norris, R J de Knegt, et al.
Pageof 7